Company intelligence / Profile preview
AcadeMab Biomedical Inc.
Taipei City, Nangang District, Taipei, Taiwanacademab.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Other
01
Overview
Currently conducting Phase 1 clinical trial of AM-928 in subjects with advanced solid tumors. AM-928 IND was cleared by US FDA and Taiwan TFDA in early 2023.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodiesmRNA vaccinesProphylactic vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Academia Sinica (exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids)
Beyond the preview
Go deeper on AcadeMab Biomedical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AcadeMab Biomedical Inc..